Jazz Pharmaceuticals plc (JAZZ)

NASDAQ: JAZZ · USD

$205

-2.17 (-1.1%)· Recorded snapshot

Market cap	13.3B
Revenue (ttm)	4.6B
Net income (ttm)	940.8M
EPS (ttm)	$14.6
Shares out	64.9M
P/E (trailing)	14.0x
P/E (forward)	10.6x
Volume	685,742
Beta	0.37

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 4.6B
Net income (ttm): 940.8M
EPS (ttm): $14.6
P/E (trailing): 14.0x
P/E (forward): 10.6x
Market cap: 13.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Mantenere

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E10.6

P25 n/aP50 n/aP75 n/a

Trailing P/E14

P25 n/aP50 n/aP75 n/a

ROE22.1

P25 n/aP50 n/aP75 n/a

ROIC17.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All JAZZ indicators

Market & fundamental data

Available fields

258

Groups with data

Currency

USD

Showing 258 of 258 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001232524
Company name	Jazz Pharmaceuticals plc
Country	Ireland
Country code	US
CUSIP number	G50871105
Earnings date	2026-11-02
Earnings time	amc
Employees	2,890
Employees change	90
Employees growth	3.21%
Enterprise value	$15.5B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2003
Industry	Biotechnology
IPO date	2007-06-01
Is primary listing	Yes
Is SPAC	No
ISIN number	IE00B4Q5ZN47
Last 10-K release date	2026-02-24
Last earnings date	2026-08-03
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$13.3B
Market cap category	Large-Cap
Next earnings date	2026-11-02
Options	Yes
Price	$204.61
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	JAZZ
Website	https://www.jazzpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	7.63x
Average P/E ratio (10Y)	45.2x
Average P/E ratio (3Y)	68.4x
Earnings yield	7.15%
EV/Earnings	16.52x
EV/EBIT	12.85x
EV/EBITDA	8.06x
EV/FCF	9.77x
EV/Sales	3.38x
FCF / EV yield	10.24%
FCF yield	11.94%
Forward EV/Sales	3.22x
Forward P/E	10.55x
Forward P/S	2.76x
Graham number	156.1994
Graham upside	-23.94%
Lynch fair value	$365.84
Lynch upside	78.15%
P/(FCF - SBC) ratio	10.38x
P/(OCF - SBC) ratio	9.84x
P/B ratio	2.79x
P/E ratio	13.98x
P/FCF ratio	8.38x
P/OCF ratio	8.03x
P/S ratio	2.9x
PEG ratio	0.2x
Price/EBITDA ratio	6.92x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	26.28%
EBITDA margin	41.88%
FCF margin	34.58%
Gross margin	91.35%
Operating margin	26.28%
Pretax margin	15.81%
Profit margin	20.45%
Profit per employee	$325,520
Profitable quarters	4
Revenue per employee	$1.6M
ROA	6.86%
ROA (5Y)	4.45%
ROCE	13.66%
ROE	22.11%
ROE (5Y)	0.6%
ROIC	17.17%
ROIC (5Y)	10.46%
SBC / revenue	6.67%
Tax / revenue	-4.63%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (QoQ)	-37.25%
EPS growth 10Y	9.78%
EPS growth 5Y	84.32%
EPS growth quarters	4
EPS growth years	0
FCF growth	25.79%
FCF growth (Q)	423.85%
FCF growth (QoQ)	2.34%
FCF growth 3Y	5.29%
FCF growth 5Y	16.11%
Gross profit growth	11.64%
Gross profit growth (Q)	17.48%
Gross profit growth 3Y	6.65%
Gross profit growth 5Y	11.49%
Net income growth (QoQ)	-34.22%
Net income growth 5Y	87.9%
Net income growth quarters	4
Net income growth years	0
OCF growth	26.23%
OCF growth (Q)	368.13%
OCF growth (QoQ)	1.84%
OCF growth 10Y	11.22%
OCF growth 3Y	6.44%
OCF growth 5Y	16.6%
Operating income growth	30.23%
Operating income growth (Q)	48.49%
Operating income growth 3Y	13.74%
Operating income growth 5Y	16.06%
Revenue growth	12.59%
Revenue growth (Q)	15.55%
Revenue growth (QoQ)	13.04%
Revenue growth 10Y	12.64%
Revenue growth 3Y	6.93%
Revenue growth 5Y	11.87%
Revenue growth quarters	5
Revenue growth years	20

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-69.8M
Depreciation and amortization	$718M
EBIT	$1.2B
EBITDA	$1.9B
EPS	$14.63
FCF per share	$24.51
Financing cash flow	$-1B
Free cash flow	$1.6B
Free cash flow minus SBC	$1.3B
Gross profit	$4.2B
Income taxes	$-213.2M
Investing cash flow	$-221.9M
Net borrowing	$-1B
Net cash flow	$429.9M
Net income	$940.8M
Operating cash flow minus SBC	$1.4B
Operating income	$1.2B
Revenue	$4.6B
Stock-based compensation	$306.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.08
Book value per share	$74.10
Debt / EBITDA	2.25
Debt / equity	0.92
Debt / FCF	2.77
Goodwill	$1.8B
Interest coverage	4.67
Long-term assets	$7.1B
Long-term liabilities	$4B
Net cash (debt)	$-2.2B
Net cash / market cap	-16.57%
Net debt / EBITDA	1.15
Net debt / equity	0.46
Net debt / FCF	1.39
Piotroski F-Score	7
Property, plant and equipment	$264.1M
Shareholders' equity	$4.8B
Tangible book value	$-1B
Tangible book value per share	$-15.86
Total assets	$11.1B
Total cash	$2.2B
Total debt	$4.4B
Total liabilities	$6.3B
WACC	5.87%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.42
Current assets	$4B
Current liabilities	$2.2B
Current ratio	1.78
Inventory turnover	0.84
Net working capital	$568.3M
Quick ratio	1.38
Working capital	$1.7B
Working capital turnover	3.05

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-5.4%
Dividend yield	0%
Shareholder yield	-5.4%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	71.6%
10Y return CAGR	5.55%
10Y total return	71.6%
150-day SMA	$229.91
15Y price change	412.87%
15Y return CAGR	11.52%
15Y total return	412.87%
1D price change	-1.05%
1M price change	-14.09%
1M total return	-14.09%
1W price change	-4.36%
1W total return	-4.36%
1Y price change	46.72%
1Y return CAGR	46.76%
1Y total return	46.72%
20-day SMA	$217.47
200-day SMA	$216.17
3M price change	-19.97%
3M total return	-19.97%
3Y price change	62.16%
3Y return CAGR	17.48%
3Y total return	62.16%
50-day SMA	$233.49
50-day SMA vs 200-day SMA	50over200
52-week high	$266.38
52-week high date	2026-08-25
52-week low	$128.80
52-week low date	2025-11-07
5Y price change	52.61%
5Y return CAGR	8.82%
5Y total return	52.61%
6M price change	1.6%
6M total return	1.6%
All-time high	$266.38
All-time high date	2026-08-25
All-time low	$0.52
All-time low date	2009-04-22
Average true range (ATR)	$6.43
Average volume	788.5K
Beta (1Y)	-0
Beta (2Y)	0.68
Beta (5Y)	0.37
Change from 52-week high	-23.19%
Change from 52-week low	58.86%
Change from all-time high	-23.25%
Change from all-time low	39,595.15%
Change from open	-0.12%
Day's gap	-0.93%
Dollar volume	$140.3M
High price	$205.45
Low price	$203.99
Monthly RSI	58.42
Open price	$204.86
Position in 52-week range	42.47%
Previous close	$206.78
Price vs 150-day SMA	-11.08%
Price vs 20-day SMA	-5.99%
Price vs 200-day SMA	-5.43%
Price vs 50-day SMA	-12.44%
Relative volume	0.87
RSI	30.36
Sharpe ratio	1.1
Sharpe ratio (3Y)	0.51
Sharpe ratio (5Y)	0.24
Sortino ratio	2.32
Sortino ratio (3Y)	0.97
Sortino ratio (5Y)	0.57
Volume	685.7K
Weekly RSI	39.19
YTD price change	20.25%
YTD total return	20.25%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	63M
Float percentage	97.04%
Shares change (QoQ)	4.99%
Shares change (YoY)	5.4%
Shares held by insiders	2.89%
Shares held by institutions	100.56%
Shares outstanding	64.9M
Short % of float	8.7%
Short % of shares	8.44%
Short ratio	7 days

Deeper analysis on JAZZ

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this JAZZ report

Is a complete JAZZ research report available?

No complete published report is available for Jazz Pharmaceuticals plc (JAZZ) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Jazz Pharmaceuticals plc (JAZZ)

Price

Financial snapshot

Fair-value bridge

Latest news · JAZZ

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All JAZZ indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on JAZZ

Frequently asked questions